Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 23
Filter
1.
Urologie ; 63(4): 357-360, 2024 Apr.
Article in German | MEDLINE | ID: mdl-38507087

ABSTRACT

BACKGROUND: The lack of postmortem donated organs is the background to varyingly high rates of living-donor kidney transplants worldwide. ABO blood group-incompatible living-donor kidney transplants have also been established for at least 20 years. The equivalence of the results of ABO-incompatible and ABO-compatible transplants has recently been questioned. OBJECTIVE: In the sense of a critical reflection of our own kidney transplant program, we were interested in comparing ABO-incompatible with ABO-compatible living-donor kidney transplants. MATERIALS AND METHODS: A retrospective analysis of the long-term outcomes of all living-donor kidney transplants performed at our center since the first ABO-incompatible transplants were performed in 2005 up to and including 2022 was performed. RESULTS: Between 2005 and 2022, 1099 living kidney transplants were performed at the authors' center. Among them were 241 ABO-incompatible transplants. Transplant survival was significantly lower after ABO-incompatible donation than after ABO-compatible donation. This effect consisted of an increased mortality of the recipients, especially in the early phase, and a reduced longevity of the grafts. CONCLUSION: Including ABO-incompatible pairs for living-donor kidney transplants in crossover programs can improve medical outcomes and reduce costs.


Subject(s)
Kidney Transplantation , Humans , Kidney Transplantation/methods , Retrospective Studies , Living Donors , ABO Blood-Group System , Kidney
2.
Transplant Proc ; 50(10): 3232-3241, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30577191

ABSTRACT

BACKGROUND: Outcomes of patients with end-stage renal disease are mainly affected by their comorbidities. Detailed data evaluating the impact of pre-transplant comorbidities on long-term outcome after kidney transplantation are largely missing. METHODS: In a long-term retrospective analysis, we investigated 839 deceased donor kidney transplant recipients (KTRs) who received transplants between 1999 and 2014. The prevalence and impact of the most relevant comorbidities were studied in detail. RESULTS: At the time of transplantation, 25% of KTRs had coronary artery disease (CAD), 16% had diabetes mellitus (DM), 11% had peripheral arterial disease (PAD), 8% had chronic heart failure (CHF), and 7% had cerebrovascular disease (CVD). KTRs with pre-existing CAD, DM, PAD, and CHF showed a significantly inferior patient survival. Multivariate analysis adjusting for all relevant factors and comorbidities confirmed CAD as most hazardous independent risk factor for premature death (hazard ratio [HR] 1.70; P = .002). A multivariate analysis revealed CHF and PAD as independent risk factors for death censored graft loss (HR 2.20; P = .003 and HR 1.80; P = .013). Diabetes was independently and significantly associated with T-cell- (HR 1.46; P = .020) and antibody-mediated rejections (HR 2.27; P = .030). CONCLUSIONS: Detailed quantification of the impact of pre-transplant comorbidities may facilitate the evaluation of transplant candidates, guide post-transplant follow-up, and may help to further refine prediction algorithms and allocation systems.


Subject(s)
Comorbidity , Kidney Failure, Chronic , Kidney Transplantation/mortality , Transplant Recipients , Adult , Aged , Diabetes Mellitus/epidemiology , Female , Graft Survival , Heart Failure/epidemiology , Humans , Kidney Transplantation/adverse effects , Male , Middle Aged , Multivariate Analysis , Peripheral Arterial Disease/epidemiology , Prevalence , Proportional Hazards Models , Retrospective Studies , Risk Factors
3.
Transplant Proc ; 47(8): 2346-50, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26518923

ABSTRACT

The lack of donors is favoring living kidney donor (LKD) transplantation worldwide, quite often beyond the classic age-matching rules. We analysed renal function (RF) at 1 and 5 years in all donor and recipients as well as death-censored graft and patient survival. LKD recipients were divided into 4 subgroups: young recipients-young donors (YR-YD; N = 355), elderly recipients-young donors (ER-YD; N = 13), young recipients-elderly donors (YR-ED; N = 67), and elderly recipients-elderly donors (ER-ED; N = 38). "Elderly" was defined as ≥60 years. RF was better in those who received a young allograft (YR-YD/ER-YD) at any time (P < .001). There was a trend toward higher proteinuria among the recipients of an old allograft (YR-ED/ER-ED) at any time (P = not significant [NS]). However, our population showed low levels of proteinuria and this was not a risk factor for graft failure. Logistic regression model showed that creatinine level at 1 year is a good predictor of graft losses. Graft survival was worse in the allografts from elderly donors (P < .001). Analysing the young recipients, renal survival was inferior in those who received an old kidney (YR-ED; P < .00005) as well as mortality rates at 14 years (P = .03). The RF of young (N = 295) and elderly donors (N = 98) was optimal with no progression to ESRD or deaths registered during follow-up. In conclusion, young recipients of elderly kidneys pay the price of a worse RF, allograft prognosis, and patient prognosis. The pair YR-ED is a doable option, but we recommend age matching when it is possible.


Subject(s)
Age Factors , Kidney Failure, Chronic/surgery , Kidney Transplantation , Living Donors , Adult , Aged , Creatinine/blood , Female , Graft Survival , Humans , Kidney Failure, Chronic/blood , Male , Middle Aged , Proteinuria , Retrospective Studies , Risk Factors , Survival Rate , Transplantation, Homologous
4.
Am J Transplant ; 12(5): 1192-8, 2012 May.
Article in English | MEDLINE | ID: mdl-22300538

ABSTRACT

Donor-specific HLA antibodies (DSA) have a negative impact on kidney graft survival. Therefore, we analyzed the occurrence of DSA and antibody-mediated rejection (AMR) in patients from two prospective randomized trials in our center. At 3-4.5 months posttransplant 127 patients were randomized to continue cyclosporine or converted to everolimus therapy. The presence of DSA was prospectively assessed using Luminex assays. AMR was defined according to the Banff 2009 classification. Antibody screening was available in 126 patients with a median follow-up of 1059 days. Seven out of 65 (10.8%) patients on cyclosporine developed DSA after a median of 991 days. In comparison, 14/61 patients (23.0%) randomized to everolimus developed DSA after 551 days (log-rank: p = 0.048). Eight patients on everolimus compared to two patients on cyclosporine developed AMR (log-rank: p = 0.036). Four of 10 patients with AMR-all in the everolimus group-lost their graft. A multivariate regression model revealed everolimus, >3 mismatches and living donor as significant risk factors for DSA. Acute rejection within the first year, >3 mismatches, everolimus and living donor were independent risk factors for AMR. This single center analysis demonstrates for the first time that everolimus-based immunosuppression is associated with an increased risk for the development of DSA and AMR.


Subject(s)
Cyclosporine/therapeutic use , Graft Rejection/drug therapy , HLA Antigens/immunology , Immunosuppressive Agents/therapeutic use , Isoantibodies/adverse effects , Kidney Transplantation/immunology , Sirolimus/analogs & derivatives , Adolescent , Adult , Aged , Child , Child, Preschool , Everolimus , Female , Follow-Up Studies , Graft Rejection/etiology , Graft Survival/immunology , Humans , Isoantibodies/blood , Isoantibodies/immunology , Male , Middle Aged , Prognosis , Prospective Studies , Risk Factors , Sirolimus/therapeutic use , Survival Rate , Tissue Donors , Young Adult
5.
Eur J Clin Pharmacol ; 68(6): 913-22, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22274404

ABSTRACT

PURPOSE: Since many drug targets and metabolizing enzymes are developmentally regulated, we investigated a potential comparable regulation of inosine 5'-monophosphate dehydrogenase (IMPDH) activity that has recently been advocated as a pharmacodynamic biomarker of mycophenolic acid (MPA) effects in the paediatric population. Since the field of pharmacodynamic monitoring of MPA is evolving, we also analyzed the response of IMPDH activity on MPA in children vs adolescents after renal transplantation. METHODS: We analyzed IMPDH activity in peripheral blood mononuclear cells (PBMCs) in 79 healthy children aged 2.0-17.9 years in comparison to 106 healthy adults. Pharmacokinetic/pharmacodynamic profiles of MPA and IMPDH over 6 or 12 h after mycophenolate mofetil dosing were performed in 17 paediatric renal transplant recipients. IMPDH activity was measured by HPLC and normalized to the adenosine monophosphate (AMP) content of the cells, MPA plasma concentrations were measured by HPLC. RESULTS: Inosine 5'-monophosphate dehydrogenase activity displayed a high inter-individual variability (coefficient of variation 40.2%) throughout the entire age range studied. Median IMPDH did not differ significantly in healthy pre-school children (82 [range, 42-184] µmol/s/mol AMP), school-age children (61 [30-153]), adolescents (83 [43-154]) and healthy adults (83 [26-215]). Similar to adults, IMPDH activity in children and adolescents was inversely correlated with MPA plasma concentration. CONCLUSIONS: In conclusion, our data do not show a pronounced developmental regulation of IMPDH activity in PBMCs in the paediatric population and there is a comparable inhibition of IMPDH activity by MPA in children and adolescents after renal transplantation.


Subject(s)
Enzyme Inhibitors/pharmacology , Enzyme Inhibitors/pharmacokinetics , IMP Dehydrogenase/blood , IMP Dehydrogenase/metabolism , Kidney Transplantation , Mycophenolic Acid/pharmacology , Mycophenolic Acid/pharmacokinetics , Adolescent , Adult , Age Factors , Child , Child, Preschool , Female , Humans , Kidney/drug effects , Kidney/metabolism , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/enzymology , Leukocytes, Mononuclear/metabolism , Male , Mycophenolic Acid/antagonists & inhibitors
7.
Transplant Proc ; 42(10): 4509-12, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21168726

ABSTRACT

BACKGROUND: Rejection still has a fundamental impact on patient and graft survivals after renal transplantation. Published studies vary widely in their reporting of biopsy-proven acute rejection (BPAR) and non-BPAR rates. We undertook a systematic search of existing publications for reasons explaining this difference. Additionally, we analyzed our own population, which has a clearly defined biopsy strategy, to further investigate the rate of non-BPAR in routine clinical practice. METHODS: From large, multicenter, randomized, controlled trials investigating immunosuppressive regimens in de novo kidney transplant recipients, we extracted the rates of all reported rejections ("total" rate) versus BPAR. Non-BPAR was defined as the difference between "total" and BPAR. Additional analyses were performed for potential influencing factors, such as year of publication, number, and mean age of patients recruited and impact factor of the journal at the time of publication. We scanned all de novo adult patients undergoing kidney transplantation in our center between 1996 and 2004 for rejection episodes during the first year. RESULTS: The median rate of non-BPAR within the first year in 27 papers was 7% (range, 0%- 16.9%). Similarly, the relative proportion of non-BPAR showed large differences. We could not identify potential influencing factors to explain the large variability. Among our population, 136/365 patients (37.3%) experienced acute rejection episodes, with BPAR diagnosed in 90/365 patients (24.7%), yielding an absolute 12.6% rate of non-BPAR. CONCLUSION: Even centers with a well-defined biopsy strategy show a substantial proportion of non-BPAR episodes. Therefore, complete reporting of both BPAR and non-BPAR is important for the proper interpretation of study results.


Subject(s)
Graft Rejection , Kidney Transplantation , Biopsy , Humans
8.
Clin Nephrol ; 67(3): 164-75, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17390741

ABSTRACT

BACKGROUND: The lower limit of exposure to calcineurin inhibitors has not yet been established in de novo renal transplant patients receiving mycophenolic acid therapy with basiliximab. METHODS: A 12-month, multicenter, randomized, open-label trial was carried out in which de novo renal transplant patients received enteric-coated mycophenolate sodium, cyclosporine microemulsion, steroids and basiliximab. Patients were randomized to receive standard-exposure (n = 45) or reduced-exposure (n = 44) cyclosporine, based on differing C2 target ranges, after the first month post-transplant. RESULTS: Cyclosporine exposure gradually increased over the first month and was lower than previously recommended. Mean calculated creatinine clearance (primary end-point) was similar in the standard-exposure and reduced-exposure groups at month 6 (55.3+/-3.2 ml/min and 61.5+/-3.7 ml/min respectively, n.s.). There were 4 deaths but no death-censored graft losses, resulting in 95.5% patient and graft survival at one year in both groups. At 6 and 12 months, the incidence of biopsy-proven acute rejection was 17.8% and 17.8% in the standard-exposure group, and 13.6% and 15.9% in the reduced-exposure group. Adverse events were similar between treatment groups. Exploratory analyses could not identify a lower limit for the optimal CsA exposure range, but results suggested that high exposure at one year was associated with deteriorating renal function. CONCLUSIONS: These results indicate that enteric-coated mycophenolate sodium with reduced-exposure cyclosporine, steroids and basiliximab induction has an excellent therapeutic effect and is safe in de novo kidney transplant recipients. Lower C2 targets than previously recommended, particularly early post-transplant, do not appear to be associated with compromised efficacy.


Subject(s)
Antibodies, Monoclonal/administration & dosage , Cyclosporine/therapeutic use , Enzyme Inhibitors/administration & dosage , Graft Rejection/drug therapy , Immunosuppressive Agents/administration & dosage , Kidney Transplantation/adverse effects , Mycophenolic Acid/administration & dosage , Recombinant Fusion Proteins/administration & dosage , Acute Disease , Adolescent , Adult , Aged , Antibodies, Monoclonal/therapeutic use , Basiliximab , Belgium/epidemiology , Biopsy , Creatinine/blood , Cyclosporine/administration & dosage , Dose-Response Relationship, Drug , Drug Administration Routes , Drug Therapy, Combination , Emulsions , Enzyme Inhibitors/therapeutic use , Female , Follow-Up Studies , Germany/epidemiology , Graft Rejection/blood , Graft Rejection/pathology , Humans , Immunosuppressive Agents/therapeutic use , Kidney Transplantation/pathology , Male , Middle Aged , Mycophenolic Acid/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Survival Rate , Tablets, Enteric-Coated , Time Factors , Treatment Outcome
9.
Am J Transplant ; 7(4): 888-98, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17391132

ABSTRACT

The aim of this single-center crossover substudy was to assess pharmacokinetics and pharmacodynamics [inosine 5'-monophosphate dehydrogenase (IMPDH) activity] of enteric-coated mycophenolate sodium (EC-MPS) and mycophenolate mofetil (MMF) at steady-state conditions. Stable maintenance renal transplant patients on 1 g MMF b.i.d. participating in a double-blind, multicenter study, were randomized to receive EC-MPS (720 mg b.i.d.) or continue receiving MMF (1000 mg b.i.d.) for 12 months. Thereafter, all patients (n = 18) received 720 mg EC-MPS b.i.d. Area under the plasma mycophenolic acid (MPA) concentration-time curve with EC-MPS (57.4 +/- 15.0 microg h/mL) fulfilled bioequivalence criteria (geometric mean 0.98 (90% CI: 0.87-1.11) compared to MMF (58.4 +/- 14.1 microg h/mL). Consistent with the delayed release characteristics of EC-MPS, peak MPA concentration (geometric mean 0.89; 90% CI: 0.70-1.13) occurred approximately 0.5 h later (p < 0.05) and predose MPA levels (geometric mean 2.10; 90% CI: 1.51-2.91) were higher and more variable, not fulfilling bioequivalence criteria. IMPDH activity inversely followed MPA concentrations and was inhibited to a similar degree (approximately 85%) by both formulations. The calculated value for 50% IMPDH inhibition was identical for both drugs. In conclusion, equimolar doses of EC-MPS and MMF produce equivalent MPA exposure, while the delayed release formulation of EC-MPS exhibits more variable predose levels and T(max). Overall, IMPDH activity reflected MPA pharmacokinetics.


Subject(s)
Kidney Transplantation/immunology , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/pharmacokinetics , Mycophenolic Acid/therapeutic use , Adult , Body Mass Index , Double-Blind Method , Drug Administration Schedule , Female , Humans , IMP Dehydrogenase/metabolism , Male , Middle Aged , Mycophenolic Acid/administration & dosage , Tablets, Enteric-Coated
10.
Transplant Proc ; 38(7): 2292-4, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16980068

ABSTRACT

The aim of this study was to assess the effects of 1 g of mycophenolate mofetil (MMF) on T-cell function and inosine monophosphate dehydrogenase (IMPDH) activity among patients undergoing kidney transplantation. Five patients undergoing renal transplantation from a living donor were enrolled in this study. Compared to baseline (before MMF intake), CD25 and CD71 expression were significantly decreased during the first hour following MMF intake. T-cell proliferation and IMPDH activity also decreased dramatically. Thereafter, all biomarker levels increased over time. At 4 hours, CD25 and CD71 levels, as well as IMPDH activity, returned to almost baseline values, whereas T-cell proliferation remained below baseline. Intracytoplasmic IL-2 expression remained unchanged after MMF ingestions. In conclusion, administration of 1 g of MMF was associated with a transient decrease in CD25 expression in addition to a temporary dramatic decrease in both T-cell proliferation and IMPDH activity.


Subject(s)
IMP Dehydrogenase/metabolism , Kidney Transplantation/physiology , Mycophenolic Acid/analogs & derivatives , T-Lymphocytes/immunology , Antigens, CD/drug effects , Antigens, CD/genetics , Biomarkers , Humans , Immunosuppressive Agents/therapeutic use , Interleukin-2 Receptor alpha Subunit/drug effects , Interleukin-2 Receptor alpha Subunit/genetics , Kidney Transplantation/immunology , Living Donors , Mycophenolic Acid/therapeutic use , Receptors, Transferrin/drug effects , Receptors, Transferrin/genetics , T-Lymphocytes/drug effects
11.
Urologe A ; 45(1): 9-17, 2006 Jan.
Article in German | MEDLINE | ID: mdl-16328215

ABSTRACT

Renal transplantation is by far the best therapeutic option for end-stage kidney disease with respect to quality of life, psychosocial rehabilitation, and even patient survival. Optimal immunosuppressive therapy should provide effective prophylaxis of both acute rejection and chronic allograft dysfunction. Thus immunosuppressive therapy should help to maintain good renal function and could help to prevent premature death of the recipient. With the introduction of new immunosuppressants over the last decade a dramatic reduction of acute rejection rates from approximately 50% to 15-30% could be achieved. However, the search for novel immunosuppressive drugs continues, drugs which not only lead to effective prevention of acute rejection, but also have an impact on chronic allograft dysfunction and prevent further deterioration of this multifactorial process. Based on a short presentation of the "three signal model" of immunoactivation, the most important mechanisms and characteristics of the presently available immunosuppressants are described. Because the immunosuppressive objectives change over time, a phase-dependent adaptation is necessary. At present, most centers in Germany use an immunosuppressive combination therapy, consisting of a calcineurin inhibitor (CNI; cyclosporine or tacrolimus), a glucocorticoid (prednisolone or methylprednisolone), and mycophenolic acid (MPA), which is eventually combined with an antibody (e.g., IL-2R antibody) for induction. In contrast to the clear situation 10 years ago, highly specialized knowledge is required today with respect to mechanism of action, side effects, and potential interactions. This may enable the physician to adopt patient-oriented optimal immunosuppression. In the near future more individualized treatment options will be employed, which are adapted to the characteristics and side effects of the immunosuppressant, as well as to the characteristics of the donor, the recipient, and the transplanted organ such as immunology and ischemia. Another aspect is the reduction or elimination of some immunosuppressants at the earliest possible time. With new diagnostic and genetic markers the relationship between recipient and transplanted organ will be characterized better in the future and therapy will become more individualized. Altogether, these measures as well as optimized supportive therapy will help to further improve the longevity of the transplanted organ.


Subject(s)
Graft Enhancement, Immunologic/methods , Graft Rejection/prevention & control , Graft Survival/drug effects , Immunosuppressive Agents/administration & dosage , Kidney Failure, Chronic/drug therapy , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Chemotherapy, Adjuvant/trends , Humans , Immunosuppressive Agents/adverse effects , Kidney Failure, Chronic/complications , Practice Guidelines as Topic , Practice Patterns, Physicians'/trends , Treatment Outcome
12.
Eur J Med Res ; 10(4): 169-74, 2005 Apr 20.
Article in English | MEDLINE | ID: mdl-15946913

ABSTRACT

The novel macrocyclic immunosuppressant everolimus has been approved for use in renal and heart transplantation. The objective of this randomized, double-blind, placebo-controlled, dose-escalating Phase 1 study was to evaluate the pharmacokinetic profile of different dosing regimens of everolimus. Fifty-four subjects were randomized for 4-weeks treatment with everolimus (n = 44) or placebo (n = 10). Steady state was reached by day 4 of multiple dosing with evidence for dose-proportionality over the dose range tested. Systemic accumulation was 1.6- to 2.2-fold with multiple dosing. Steady-state predose trough concentrations were well correlated with AUC (r = 0.87, p < 0.001). Within-subject coefficients of variation for the tablet formulation ranged from 10-19% and between-subject coefficients from 34-60% for Cmax and AUC. There was no effect of common demographic parameters (age, sex, weight) on variability in steady-state exposure. These results support the clinical use of everolimus in renal transplantation.


Subject(s)
Immunosuppressive Agents/pharmacokinetics , Kidney Transplantation/immunology , Sirolimus/analogs & derivatives , Sirolimus/pharmacokinetics , Area Under Curve , Biological Availability , Cohort Studies , Demography , Dose-Response Relationship, Drug , Double-Blind Method , Everolimus , Humans , Immunosuppressive Agents/therapeutic use , Metabolic Clearance Rate , Placebos , Sirolimus/therapeutic use
13.
Eur J Med Res ; 10(4): 175-8, 2005 Apr 20.
Article in English | MEDLINE | ID: mdl-15946914

ABSTRACT

UNLABELLED: The present study sought to validate the concept of C2 monitoring in 41 de-novo transplant patients treated with microemulsion of cyclosporine, mycophenolatesodium, steroids and basiliximab. RESULTS: After 6 months patient and graft survival was 98%, rejection rate was 19%. In the first week only a few patients achieved the suggested C2 levels (19% > 1500, 50% > 1200 ng/ml) despite an increased cyclosporine (CsA) dose. After 14 days 63% of patients reached C2 > 1500 ng/ml (83% C2 > 1200) despite decreased CsA dose. 35% of patients had intermittent high C0 (> 300) and low C2 (< 800), suggesting poor and/or slow absorption. Most of them suffered from CsA toxicity. There was a significant (p < 0.05) change of absorption as measured by C2/C0 leading to an increase of C2/dose. CONCLUSIONS: C2 monitoring may be useful to better estimate the CsA exposure in individual patients; however our results indicate some limitations of the current concept of C2 monitoring. Despite increase of dosage many patients do not reach the proposed levels. A significant proportion of patients are poor and/or slow absorbers. CsA toxicity may not be detected by C2 monitoring alone. With the use of basiliximab and mycophenolatesodium lower target levels seem to be sufficient.


Subject(s)
Complement C2/metabolism , Cyclosporine/pharmacokinetics , Drug Monitoring , Immunosuppressive Agents/pharmacokinetics , Intestinal Absorption/physiology , Kidney Transplantation/immunology , Kidney/drug effects , Antibiotics, Antineoplastic/therapeutic use , Antibodies, Monoclonal/therapeutic use , Basiliximab , Cyclosporine/therapeutic use , Drug Therapy, Combination , Graft Rejection , Graft Survival , Humans , Immunosuppressive Agents/therapeutic use , International Agencies , Mycophenolic Acid/therapeutic use , Recombinant Fusion Proteins/therapeutic use , Steroids/therapeutic use
14.
Transplant Proc ; 36(2 Suppl): 524S-527S, 2004 Mar.
Article in English | MEDLINE | ID: mdl-15041401

ABSTRACT

Mycophenolate mofetil (MMF), in combination with cyclosporine and corticosteroids, improves long-term graft function and survival in renal transplant recipients. However, optimal MMF therapy may be limited by gastrointestinal (GI) intolerance, which may result in the need for MMF dose reduction, interruption, or discontinuation, leading to increased risk of acute rejection. Enteric-coated mycophenolate sodium (EC-MPS) is an advanced formulation delivering mycophenolic acid (MPA), developed with the objective of improving MPA-related upper GI adverse events. A pivotal, 12-month, phase III, randomized, multicenter, double-blind, double-dummy, parallel group study investigated whether stable renal transplant patients can be converted from MMF to EC-MPS therapy without compromising tolerability or efficacy. Stable renal transplant recipients received either MMF, 1000 mg b.i.d. (n=159), or EC-MPS, 720 mg b.i.d. (n=163), for 12 months. The incidence of GI adverse events was comparable between both treatment groups at 3 and 6 months, but there was a trend toward reduced severity of GI side effects in the EC-MPS group. There were fewer serious adverse events with EC-MPS and significantly fewer serious infections (P<.05). This comparable safety profile for EC-MPS and MMF also extended to elderly patients and patients with diabetes at baseline. For the composite efficacy variable of biopsy-proven acute rejection, graft loss, death, or loss to follow-up, EC-MPS had a lower 12-month efficacy failure rate (EC-MPS: 7.5% vs MMF: 12.3%; P=ns). These data demonstrate that stable renal transplant recipients receiving MMF can be converted to EC-MPS with no efficacy or tolerability compromise.


Subject(s)
Kidney Transplantation/immunology , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Adult , Aged , Costs and Cost Analysis , Female , Gastrointestinal Diseases/chemically induced , Gastrointestinal Diseases/epidemiology , Germany , Graft Survival/drug effects , Graft Survival/physiology , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Mycophenolic Acid/administration & dosage , Mycophenolic Acid/adverse effects , Mycophenolic Acid/economics , Tablets, Enteric-Coated
15.
Int J Clin Pharmacol Ther ; 41(10): 470-6, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14703953

ABSTRACT

OBJECTIVE: Mycophenolate mofetil (MMF) is routinely used as an immunosuppressant in a fixed daily dose regimen although it shows marked fluctuations in pharmacokinetics, and despite the fact that in regard to the active metabolite, mycophenolic acid (MPA), there is a well-known association between the pharmacokinetic parameters and clinical outcome. METHOD: In order to determine the time course and the variability in cellular target of MPA after renal transplantation, we investigated the pharmacodynamic response in 8 patients receiving 1 g MMF for the first time prior to renal transplantation and in 8 stable renal transplant patients maintained on long-term MMF therapy (1 g b.i.d.) for more than 1 year. The pharmacodynamic response was measured using inosine 5'-monophosphate dehydrogenase (IMPDH) activity in peripheral mononuclear cells. MPA plasma concentrations were measured in parallel, IMPDH activity in 89 healthy blood donors was used as a control. RESULTS: We observed a high interindividual variability in IMPDH activity in the 89 untreated healthy volunteers (4.0 - 32.9 nmol/h/mg protein), in 8 patients on dialysis (5.3 - 18.9 nmol/h/mg protein) and in 8 renal transplant patients under long-term MMF treatment (2.3 - 14.4 nmol/h/mg protein). The mean AUC0-12h for mycophenolic acid was 2-fold higher in patients receiving long-term treatment with MMF (62.2 +/- 16.6 mg x h/ml) compared to dialysis patients receiving 1 g MMF for the first time (31.5 +/- 15.6 mg x h/ml). Despite this pharmacokinetic difference there were no statistically significant differences in the cellular pharmacodynamic response. Minimal IMPDH activity (1.62 +/- 1.23 vs. 1.77 +/- 1.49 nmol/h/mg protein) and maximal IMPDH inhibition (87.5 +/- 0.08 vs. 77.4 +/- 18.8%) during the dosing interval were similar. CONCLUSIONS: The considerable interindividual variability in the pharmacokinetics of MMF as well as in the drug target support the use of pharmacodynamic drug monitoring to optimize MMF dosing and to reduce the risk of graft rejection and side effects.


Subject(s)
Enzyme Inhibitors/therapeutic use , Graft Rejection/prevention & control , IMP Dehydrogenase/antagonists & inhibitors , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Mycophenolic Acid/analogs & derivatives , Mycophenolic Acid/therapeutic use , Prodrugs/therapeutic use , Area Under Curve , Enzyme Inhibitors/pharmacokinetics , Female , Humans , IMP Dehydrogenase/metabolism , Male , Middle Aged , Mycophenolic Acid/pharmacokinetics , Prodrugs/pharmacokinetics , Renal Dialysis
16.
Int J Clin Pharmacol Ther ; 41(10): 477-81, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14703954

ABSTRACT

Therapeutic drug monitoring of cyclosporin A (CsA) is essential because of its variable pharmacokinetics in individual patients and its narrow therapeutic window. In the past, standard trough level (C0) monitoring has been used, and although this method is currently the routine strategy, it has been shown that a single blood concentration measurement 2 hours after CsA administration (C2hour) is a significantly more accurate predictor of drug exposure and clinical events than trough concentrations. The CsA absorption profiling, in particular the measurement of C2hour, is a much more sensitive approach to assessing the pharmacokinetics and predicting the clinical effect in the individual patient. However, there are limited prospective data available examining the risks and benefits of C2hour monitoring in renal transplant recipients. Most studies focus on the early post-transplant phase, but there is little experience with C2hour monitoring in maintenance patients. Our experience in 127 stable long-term renal allograft recipients suggests that the therapeutic window for C2hour levels in patients during maintenance is lower than previously anticipated. Repeat determinations of both C0 and C2hour levels in 46 patients to determine precision of C2hour monitoring showed a high intrapatient variability. We observed only a slightly better coefficient of variation for C2hour than for C0 in repeat determinations. This suggests that drug monitoring using C2hour levels in transplant patients may provide a more accurate and reliable measure of drug exposure in the individual patient. However, CsA absorption showed only a weak correlation with dose during repeated measurements, suggesting high variability in absorption in these stable patients. We conclude that an adequate C2hour level soon after transplantation is associated with a reduced risk of acute rejection in adult renal transplant recipients. It is important to identify slow and poor absorbers in the initial phase after transplantation in order to avoid inappropriate increases in CsA dose. In maintenance patients, C2hour values between 500 and 600 ng/ml are effective and safe for providing effective rejection prophylaxis. Although mean C2hour levels do not seem to identify patients at risk of rejection, they may help to identify excessive immunosuppression and to improve long-term survival by reducing CsA toxicity.


Subject(s)
Cyclosporine/therapeutic use , Drug Monitoring/methods , Graft Rejection/prevention & control , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Absorption , Adult , Area Under Curve , Cyclosporine/blood , Cyclosporine/pharmacokinetics , Humans , Immunosuppressive Agents/blood , Immunosuppressive Agents/pharmacokinetics , Time Factors , Tissue Distribution
17.
Int J Clin Pharmacol Ther ; 41(10): 488-91, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14703956

ABSTRACT

The advent of new antidiabetic drugs is of special importance for diabetic patients with already impaired renal function since renal insufficiency is a relative or absolute contraindication for several of the established hypoglycemic drugs. Pioglitazone is a novel oral hypoglycemic agent that increases insulin responsiveness in target tissues. Pioglitazone and its active metabolites are excreted mainly via the liver. Drug exposure remains almost constant across a wide range of renal function since there is no accumulation of the drug or its active metabolites during repeated dosing in renal insufficiency. The pharmacokinetic properties of pioglitazone are ideally suited for patients with renal insufficiency. Although there are possible side effects (mainly fluid retention and weight gain and--very rarely--hepatotoxicity). Pioglitazone has a good safety profile in diabetic patients with impaired renal function.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/prevention & control , Hypoglycemic Agents , Thiazolidinediones , Area Under Curve , Diabetes Mellitus, Type 2/metabolism , Diabetic Nephropathies/metabolism , Humans , Hypoglycemic Agents/metabolism , Hypoglycemic Agents/pharmacokinetics , Hypoglycemic Agents/therapeutic use , Liver/drug effects , Liver/metabolism , Metabolic Clearance Rate , Pioglitazone , Thiazolidinediones/metabolism , Thiazolidinediones/pharmacokinetics , Thiazolidinediones/therapeutic use
20.
Clin Biochem ; 34(7): 543-9, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11738390

ABSTRACT

BACKGROUND: The immunosuppressive activity of mycophenolate mofetil (MMF) is based on the reversible inhibition of inosine 5'-monophosphate dehydrogenase (IMPDH) by mycophenolic acid (MPA). It was the aim of this study to develop a nonradioactive method for specific measurement of IMPDH activity in isolated peripheral mononuclear cells (MNC). METHODS: The procedure is based on the incubation of lysed MNC with inosine 5'-monophosphate (IMP) followed by direct chromatographic determination of produced xanthosine 5'-monophosphate (XMP). IMPDH activity was measured in MNC of MMF-treated patients and nontreated volunteers. RESULTS: The within-run (n = 10) and between-run (n = 20) coefficients of variation (CV) for IMPDH activity were < 8% and < 10%, respectively. IMPDH activity in 60 healthy volunteers (19-63 yr) ranged from 4.72 to 32.92 nmol/h/mg protein (mean = 18.39 +/- 6.24). The IC(50) for in vitro inhibition of IMPDH activity was about 2 to 3 microg/L. Application of a single dose of 1 g MMF in dialysis patients resulted in a significant inhibition (by 47-95%; p < 0.05) of IMPDH activity in lysed MNC. CONCLUSIONS: The proposed assay specifically and reliably measures IMPDH activity in MNC. The procedure is applicable to evaluate pharmacodynamic activity in MMF-treated patients. The observed interindividual variability of IMPDH activity may reflect pharmacodynamic differences in MMF-treated patients.


Subject(s)
IMP Dehydrogenase/analysis , Leukocytes, Mononuclear/enzymology , Mycophenolic Acid/analogs & derivatives , Adult , Chromatography, High Pressure Liquid/methods , Enzyme Inhibitors/pharmacology , Female , Humans , Male , Middle Aged , Mycophenolic Acid/pharmacology , Reproducibility of Results , Ribonucleotides/analysis , Xanthine
SELECTION OF CITATIONS
SEARCH DETAIL
...